Skip to main content

Table 3 Details of client-owned dogs enrolled in a clinical field study investigating the efficacy and safety of combination product chewable tablets administered orally once a month for 11 months for the prevention of heartworm disease in the USA

From: Laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs

Category

Treatment group

Moxidectin/ Sarolaner/Pyrantel combination product

Heartgard® Plus

Total

No. of females (intact/spayed)

139 (24/115)

65 (11/54)

204 (49.8%)

No. of males (intact/neutered)

133 (36/97)

73 (15/58)

206 (50.2%)

Mean initial age in years (range)

4.12 (0.15–13.0)

4.70 (0.25–13.0)

4.32 (0.15–13.0)

Pure-bred/mixed breed (%)

58.1/41.9

58.7/41.3

58.3/41.7

No. indoors and outdoors (%)

91 (33.5)

44 (31.9)

135 (32.9)

No. mostly indoors (%)

169 (62.1)

86 (62.3)

255 (62.2)

No. mostly outdoors (%)

12 (4.4)

8 (5.8)

20 (4.9)